133117-45-0

Basic information

• Product Name: 1-chloro-2-trimethylsilyl-3-fluorobenzene
• Synonyms: 1-chloro-2-trimethylsilyl-3-fluorobenzene
• CAS NO: 133117-45-0
• Molecular Weight: 202.731
• Mol File: 133117-45-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 105 °C(Press: 3 Torr)
• Density: 1.06±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 1-chloro-2-trimethylsilyl-3-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-chloro-2-trimethylsilyl-3-fluorobenzene(133117-45-0)
• EPA Substance Registry System: 1-chloro-2-trimethylsilyl-3-fluorobenzene(133117-45-0)

Safety Data

• Hazardous Substances Data: 133117-45-0(Hazardous Substances Data)

Usage

Physical state

Colorless liquid

Molecular weight

188.72 g/mol

Usage

Building block in organic synthesis, production of pharmaceuticals and agrochemicals, manufacturing of electronic materials, and as a reagent in chemical research

Hazard

Flammable and may release toxic fumes when heated

Safety precautions

Handle and store with proper safety measures in place

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 625-98-9 3-chlorofluorobenzene 

Downstream Products

• 87327-69-3 1-(2-chloro-6-fluorophenyl)ethan-1-one 
• 127654-70-0 1-chloro-3-fluoro-2-iodobenzene 

Relevant articles and documents

Synthesis and Biological Evaluation of an Indazole-Based Selective Protein Arginine Deiminase 4 (PAD4) Inhibitor

Protein arginine deiminase 4 (PAD4) is a calcium-dependent enzyme that catalyzes the conversion of arginine to citrulline within target proteins. Dysregulation of PAD4 has been implicated in a number of human diseases, including rheumatoid arthritis and other inflammatory diseases as well as cancer. In this study, we report on the design, synthesis, and evaluation of a new class of haloacetamidine-based compounds as potential PAD4 inhibitors. Specifically, we describe the identification of 4,5,6-trichloroindazole 24 as a highly potent PAD4 inhibitor that displays >10-fold selectivity for PAD4 over PAD3 and >50-fold over PAD1 and PAD2. The efficacy of this compound in cells was determined by measuring the inhibition of PAD4-mediated H4 citrullination in HL-60 granulocytes.